These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27690665)

  • 21. JAK inhibitors: A broadening approach in rheumatoid arthritis.
    Lam S
    Drugs Today (Barc); 2016 Aug; 52(8):467-469. PubMed ID: 27722215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
    Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
    Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baricitinib: JAK inhibition for rheumatoid arthritis.
    Gras J
    Drugs Today (Barc); 2016 Oct; 52(10):543-550. PubMed ID: 27910962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis.
    Harigai M
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i34-i42. PubMed ID: 30806708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tofacitinib for treatment of rheumatoid arthritis.
    Rakieh C; Conaghan PG
    Adv Ther; 2013 Aug; 30(8):713-26. PubMed ID: 23943546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib.
    Choy EHS; Miceli-Richard C; González-Gay MA; Sinigaglia L; Schlichting DE; Meszaros G; de la Torre I; Schulze-Koops H
    Clin Exp Rheumatol; 2019; 37(4):694-704. PubMed ID: 30767864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Janus kinase inhibitors for rheumatoid arthritis.
    Yamaoka K
    Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to Ⅱ clinical trials.
    Wu J; Zhu Z; Yu Q; Ding C
    Expert Opin Investig Drugs; 2019 Dec; 28(12):1113-1123. PubMed ID: 31738612
    [No Abstract]   [Full Text] [Related]  

  • 29. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
    Tanaka Y; Yamaoka K
    Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing available JAK inhibitors for treating patients with psoriasis.
    Funk PJ; Perche PO; Singh R; Kelly KA; Feldman SR
    Expert Rev Clin Immunol; 2022 Mar; 18(3):281-294. PubMed ID: 35129030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib.
    Kawalec P; Śladowska K; Malinowska-Lipień I; Brzostek T; Kózka M
    Ther Clin Risk Manag; 2018; 14():15-29. PubMed ID: 29317823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib.
    Nezamololama N; Fieldhouse K; Metzger K; Gooderham M
    Drugs Context; 2020; 9():. PubMed ID: 33240390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.
    Tanaka Y; Atsumi T; Amano K; Harigai M; Ishii T; Kawaguchi O; Rooney TP; Akashi N; Takeuchi T
    Mod Rheumatol; 2018 Jul; 28(4):583-591. PubMed ID: 29134891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential.
    Kuriya B; Cohen MD; Keystone E
    Ther Adv Musculoskelet Dis; 2017 Feb; 9(2):37-44. PubMed ID: 28255337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate.
    Fleischmann R
    Expert Opin Pharmacother; 2017 Oct; 18(14):1525-1533. PubMed ID: 28829236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
    Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
    Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baricitinib: First Global Approval.
    Markham A
    Drugs; 2017 Apr; 77(6):697-704. PubMed ID: 28290136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
    Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
    Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
    Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.